Delivery of systemic chemotherapeutic agent to tumors by using focused ultrasound: Study in a murine model

Radiology

Volumn 234, Issue 2, 2005, Pages 431-437

  Yuh, Esther L ^a   Shulman, Suzanne G ^b   Mehta, Shilpa A ^b   Xie, Jianwu ^b   Chen, Lili ^a   Frenkel, Victor ^b   Bednarski, Mark D ^a,b   Li, King C P ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HIGH INTENSITY FOCUSED ULTRASOUND; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPECTROFLUOROMETRY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; LIPOSOMES; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; SPECTROPHOTOMETRY; ULTRASONICS;

EID: 12344335066     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2342030889     Document Type: Article

References (50)

1. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996; 271:1079-1080.
2. Hall SS. Monoclonal antibodies at age 20: promise at last? Science 1995; 270:915-916.
3. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271:58-65.
4. Trail P, Bianchi AB. Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol 1999; 11:584-588.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
6. Torres Filho IP, Leunig M, Yuan F, Intaglietta M, Jain RK. Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Natl Acad Sci U S A 1994; 91: 2081-2085.
7. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997; 3:177-182.
8. Lankelma J, Dekker H, Luque RF, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999; 5:1703-1707.
9. Netti PA, Hamberg LM, Babich JW, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A 1999; 96:3137-3143.
10. Ranson MR, Cheeseman S, White S, Margison J. Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit Rev Oncol Hematol 2001; 37:115-120.
11. Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 1998; 4:499-505.
12. Colbern GT, Hiller AJ, Musterer RS, Working PK, Henderson IC. Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model. J Inorg Biochem 1999; 77(1-2):117-120.
13. Laverman P, Carstens MG, Boerman OC, et al. Factors affecting the accelerated blood clearance of poly-ethylene-glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 2001; 298:607-612.
14. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001; 61:3027-3032.
15. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000; 60:6950-6957.
16. Needham D, Anyarambhatla G, Kong G, Dewhirst MD. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60:1197-1201.
17. Dewhirst MW, Prosnitz L, Thrall D, et al. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin Oncol 1997; 24:616-625.
18. Huang Q, Hu JK, Lohr F, et al. Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res 2000; 60:3435-3439.
19. Uchida T, Sanghvi NT, Gardner TA, et al. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate can-a preliminary report. Urology 2002; 59:394-399.
20. Wu F, Chen WZ, Bai J, et al. Tumor vessel destruction resulting from high-intensity focused ultrasound in patients with solid malignancies. Ultrasound Med Biol 2002; 28:535-542.
21. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 1999; 161:156-162.
22. Köhrmann KU, Michel MS, Gaa J, Marlinghaus E, Alken P. High intensity focused ultrasound as noninvasive therapy for multilocal renal cell carcinoma: case study and review of the literature. J Urol 2002; 167:2397-2403.
23. Tempany CM, Stewart EA, McDannold N, Jolesz FA, Hynynen K. MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology 2003; 226:897-905.
24. Unger EC, McCreery TP, Sweitzer RH, Caldwell VE, Wu Y. Acoustically active lipospheres containing paclitaxel: a new therapeutic ultrasound contrast agent. Invest Radiol 1998; 33:886-892.
25. Keyhani K, Guzmán HR, Parsons A, Lewis TN, Prausnitz MR. Intracellular drug delivery using low-frequency ultrasound: quantification of molecular uptake and cell viability. Pharm Res 2001; 18:1514-1520.
26. Marin A, Muniruzzaman M, Rapoport N. Mechanism of ultrasonic activation of micellar drug delivery. J Control Release 2001; 75:69-81.
27. Husseini GA, Christensen DA, Rapoport NY, Pitt WG. Ultrasonic release of doxorubicin from pluronic p105 micelles stabilized with an interpreting network of N,N-diethylacrylamide. J Control Release 2002; 83:303-305.
28. Husseini GA, Runyan CM, Pitt WG. Investigating the mechanism of acoustically activated uptake of drugs from Pluronic micelles. BMC Cancer 2002; 2:20. Available at: www.biomedcentral-.com/1471-2407/2/20.
29. Anwer K, Kao G, Proctor B, et al. Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration. Gene Ther 2000; 7:1833-1839.
30. Koch S, Pohl P, Cobet U, Rainov NG. Ultrasound enhancement of liposome-mediated cell transfection is caused by cavitation effects. Ultrasound Med Biol 2000; 26:897-903.
31. Nelson JL, Roeder BL, Carmen JC, Roloff F, Pitt WG. Ultrasonically activated chemotherapeutic drug delivery in a rat model. Cancer Res 2002; 62:7280-7283.
32. Bednarski MD, Lee JW, Callstrom MR, Li KC. In vivo target-specific delivery of macromolecular agents with MR-guided focused ultrasound. Radiology 1997; 204: 263-268.
33. Arenberg DA, Keane MP, DiGiovine B, et al. Bidirectional modulation of GABA release by presynaptic glutamate receptor 5 kainate receptors in the basolateral amygdala. J Clin Invest 1998; 102:465-472.
34. Follett DH. A versatile schlieren system for beam and waveform visualization with quantitative real-time profiling capability. In: Evans JA, ed. Physics in medical ultrasound. IPSM Report no. 47. York, United Kingdom: Institute of Physical Sciences in Medicine, 1986; 85-93.
35. Hagan PL, Halpern SE, Dillman RO, et al. Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986; 27:422-427.
36. Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol 1999; 26(4 suppl 12):41-50.
37. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996; 380:561-562.
38. Lasic DD, Ceh B, Stuart MC, Guo L, Frederik PM, Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1995; 1239: 145-156.
39. Miller DL, Song J. Lithotripter shock waves with cavitation nucleation agents produce tumor growth reduction and gene transfer in vivo. Ultrasound Med Biol 2002; 28:1343-1348.
40. Simonin JP. On the mechanisms of in vitro and in vivo phonophoresis. J Control Release 1995; 33:125-141.
41. WFUMB Symposium on Safety of Ultrasound in Medicine: conclusions and recommendations on thermal and non-thermal mechanisms for biological effects of ultrasound, Kloster-Banz, Germany, April 14-19, 1996. World Federation for Ultrasound in Medicine and Biology. Ultrasound Med Biol 1998; 24(suppl 1):i-xvi, S1-S58.
42. Miller DL, Song J. Tumor growth reduction and DNA transfer by cavitation-enhanced high intensity focused ultrasound in vivo. Ultrasound Med Biol 2003; 29:887-893.
43. Kobayashi N, Yasu T, Yamada S, et al. Endothelial cell injury in venule and capillary induced by contrast ultrasonography. Ultrasound Med Biol 2002; 28:949-956.
44. Dittmar K, Xie J, Hunter F, et al. Pulsed-HIFU facilitated local gene delivery with systemically injected naked DNA in a mouse squamous cell carcinoma model: initial experience. Radiology (in press).
45. Nightingale K, Soo MS, Nightingale R, Trahey G. Acoustic radiation force impulse imaging: in vivo demonstration of clinical feasibility. Ultrasound Med Biol 2002; 28:227-235.
46. Lizzi FL, Muratore R, Deng CX, et al. Radiation-force technique to monitor lesions during ultrasonic therapy. Ultrasound Med Biol 2003; 11:1593-1605.
47. Nyborg WL, Carson PL, Miller MW, et al. Biological effects of ultrasound: mechanisms and clinical applications. NCRP Report no. 74. Washington, DC: Government Printing Office, 1983.
48. Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995; 269:850-853.
49. Frenkel V, Kimmel E, Iger Y. Ultrasound-induced intercellular space widening in fish epidermis. Ultrasound Med Biol 2000; 26:473-480.
50. Frenkel V, Kimmel E, Iger Y. Ultrasound-facilitated transport of silver chloride (AgCl) particles in fish skin. J Control Release 2000; 68:251-261.